SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MullenArmy is actively discussing a speculative push for the MULN crypto token, heavily associating it with simultaneous promotional campaigns for the DARTH symbol and various SOL-based meme coin projects. The community remains deeply polarized, with proponents rallying behind aggressive buying and rotation tactics while critics dismiss the activity as a high-risk pump-and-dump scheme reminiscent of past stock market volatility.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing intense investor interest driven by a significant surge in trading volume and momentum following the company's disclosure of early-stage mRNA-based research targeting hantavirus. The broader community remains deeply divided, with bulls highlighting the potential for long-term mRNA pipeline growth and potential short squeezes, while others remain skeptical of the stock's pandemic-era correlation and regulatory narratives.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as investors aggressively discuss its potential for a major breakout, driven by its privacy features, quantum resistance, and a supply profile similar to Bitcoin. The community is actively debating its long-term viability, with many comparing it to Bitcoin while speculating on catalysts like regulatory shifts, potential ETF interest, and comparisons to other privacy-focused assets.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

The Shiba Inu community remains highly divided, with ongoing debates centering on the asset's utility and burn mechanisms compared to emerging alternatives on newer chains like Base. While some long-term holders express conviction in a potential reversal, others are actively rotating capital into different meme tokens, citing stagnant performance and frustrations over unmet project promises.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

GigaChad is currently trending as community members highlight its recent expansion into real-world fitness products sold at major retailers and celebrate its enduring cultural presence. Investors are actively discussing the token's long-term potential compared to other established memes, with many focusing on its identity as a durable community-led project on the Solana network.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

The RAGE community is actively rallying behind the project, emphasizing its status as an 'OG' meme token and promoting its meme-creation platform to drive engagement. Investors are currently focused on 'bagworking' through viral marketing efforts, expressing high conviction in the asset's long-term potential while voicing frustrations regarding social media platform algorithms.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as traders speculate on potential ecosystem developments and technical breakout patterns, with the community actively debating whether it is a long-term utility play or a cyclical pump-and-dump scheme. Discussion is dominated by polarized sentiment between long-term holders accumulating through price volatility and vocal critics questioning the project's transparency and delivery on milestones.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

Troll is trending as the community rallies around its status as an iconic internet meme, frequently discussed alongside other OG memecoins on the Solana network. Investors are actively tracking its momentum and social utility, with ongoing discussions centered on its cultural longevity and the potential for long-term growth as a pillar of meme culture.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant momentum as investors rally behind its transition into an AI and cybersecurity-focused enterprise, fueled by institutional accumulation and the renewal of its share buyback program. The community is buzzing over the stock's recent price action, with many highlighting the critical role of QNX in the evolving physical AI and automotive sectors as a primary catalyst for long-term growth.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing intense investor focus as community members weigh the clinical progress of its obesity pipeline against recent organizational adjustments and litigation, while simultaneously speculating on the timing of a potential buyout or major partnership. The conversation remains heavily driven by the upcoming maintenance dosing study and the high-stakes race to compete with established GLP-1 sector leaders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised

MIRM beats Q1 earnings and revenue estimates as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.

Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q1 Earnings

Although the revenue and EPS for Mirum Pharmaceuticals (MIRM) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +3.47% and +8.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today reported financial results for the first quarter 2026 and provided a business update. 2026 is off to an excellent...

Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week High After Analyst Upgrade

Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week High on Analyst Upgrade...

<ul class="summary-bullets"><li>In Mirum’s trial, volixibat delivered statistically significant and clinically meaningful reductions in cholestatic pruritus or an intense, often debilitating itching caused by liver diseases.&nbsp;</li><li>The company added that it now expects topline data from a separate study of volixibat in primary biliary cholangitis in the first quarter of 2027.</li></ul> Shares of Mirum Pharmaceuticals, Inc. (MIRM) closed 10% higher on Monday, marking its best day since mid-December, after the company said that its investigational drug volixibat met the primary endpoint in a mid-stage study in patients with a rare liver disease.Primary Sclerosing Cholangitis (PSC) is a chronic, progressive, and rare liver disease characterized by inflammation, scarring, and narrowing of the bile ducts. In Mirum’s trial, volixibat delivered statistically significant and clinically meaningful reductions in cholestatic pruritus or an intense, often debilitating itching caused by liver diseases.In the primary analysis cohort of 111 patients with moderate-to-severe itch at baseline, volixibat 20 mg twice daily produced a 2.72-point improvement from baseline on a standardized scale, compared with a 1.08-point improvement for placebo, the company said. Statistically significant itch relief was observed as early as two weeks after starting therapy and was also seen in the secondary cohort of patients with mild itch, it added.Severe adverse events associated with the drug in the trial consisted mainly of gastrointestinal side effects and elevations in liver laboratory values such as ALT and bilirubin, the company said.<h2 class="st-heading-2">FDA Approval And Process</h2>The results position volixibat as a potential approved therapy for the severe itching that is one of the most burdensome symptoms of PSC, a rare and progressive liver disease with no approved treatments, according to Mirum’s chief medical officer Joanne Quan.Mirum said it has scheduled a pre-New Drug Application meeting with the U.S. Food and Drug Administration for this summer and plans to submit an NDA in the second half of 2026. The company added that it now expects topline data from a separate study of volixibat in primary biliary cholangitis in the first quarter of 2027.<h2 class="st-heading-2">How Did MIRM Retail Traders React?</h2>On Stocktwits, retail sentiment around MIRM jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A Stocktwits user voiced optimism for a buyout at up $160/share price.<stembedurl>https://www.stocktwits.com/BZAJDEL/message/652215094</stembedurl><a href="https://stocktwits.com/symbol/MIRM">MIRM stock </a>has gained about 140% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ford-warns-of-no-fair-fight-with-chinese-evs-while-byd-dwarfs-its-april-output/cZQu5XdReJq">Ford Warns Of ‘No Fair Fight’ With Chinese EVs While BYD Dwarfs Its April Output</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Mirum Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium

Mirum said it has scheduled a pre-New Drug Application meeting with the U.S. Food and Drug Administration for this summer to discuss its drug volixibat in the treatment of Primary Sclerosing Cholangitis. 

Equity

Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down - What's Next?

Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down - Here's Why...

Mirum Pharmaceuticals Says Volixibat Phase IIb VISTAS Hits Endpoint, Cuts PSC Itch vs Placebo

Mirum Pharmaceuticals (NASDAQ:MIRM) said its Phase IIb VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC) met its primary endpoint, showing a statistically significant reduction in cholestatic pruritus compared with placebo, according to executives on the company's busin...

HC Wainwright Forecasts Strong Price Appreciation for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

HC Wainwright lifted their price objective on Mirum Pharmaceuticals from $150.00 to $175.00 and gave the company a "buy" rating in a report on Monday...

Mirum Pharma's Phase 2b Study Of Volixibat For Sclerosing Cholangitis Meets End Point, Shares Gain

(RTTNews) - Mirum Pharmaceuticals, Inc. (MIRM), Monday said that its VISTAS Phase 2b study evaluating Volixibat met primary endpoint in patients with primary sclerosing cholangitis or PSC. The...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Mirum Pharmaceuticals Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.78	--	--	N/A
Q1 '26	-$0.37	-$13.43	-3576.76%	MISSED
Q4 '25	$0.06	-$0.10	-280.15%	MISSED
Q3 '25	-$0.14	$0.05	135.67%	BEAT
Q2 '25	-$0.33	-$0.12	63.22%	BEAT

MIRM
Mirum Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest MIRM News

MIRMMirum Pharmaceuticals Inc